These agents successfully suppressed CD44 expression in sorafenib insensitive, mesenchymal-like HCC cells while rapamycin and its analog, everolimus did not (Figure 2, Supplementary Figure 3). The gene discussed is CD44; the disease is hepatocellular carcinoma.